Log in

Veracyte Stock Forecast, Price & News

+0.14 (+0.43 %)
(As of 09/18/2020 09:42 PM ET)
Today's Range
Now: $32.72
50-Day Range
MA: $33.05
52-Week Range
Now: $32.72
Volume1.19 million shs
Average Volume529,390 shs
Market Capitalization$1.66 billion
P/E RatioN/A
Dividend YieldN/A
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More
Veracyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:VCYT



Sales & Book Value

Annual Sales$120.37 million
Book Value$4.90 per share


Net Income$-12,600,000.00


Market Cap$1.66 billion
Next Earnings Date10/27/2020 (Estimated)
+0.14 (+0.43 %)
(As of 09/18/2020 09:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Veracyte (NASDAQ:VCYT) Frequently Asked Questions

How has Veracyte's stock price been impacted by Coronavirus?

Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VCYT shares have increased by 38.9% and is now trading at $32.72.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Veracyte?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Veracyte

When is Veracyte's next earnings date?

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Veracyte

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.22) EPS for the quarter, hitting analysts' consensus estimates of ($0.22). The biotechnology company earned $20.70 million during the quarter, compared to the consensus estimate of $17.56 million. Veracyte had a negative net margin of 27.49% and a negative return on equity of 13.35%.
View Veracyte's earnings history

What price target have analysts set for VCYT?

4 analysts have issued 1 year target prices for Veracyte's stock. Their forecasts range from $35.00 to $40.00. On average, they expect Veracyte's share price to reach $37.25 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price.
View analysts' price targets for Veracyte

Are investors shorting Veracyte?

Veracyte saw a decline in short interest in August. As of August 14th, there was short interest totaling 4,550,000 shares, a decline of 23.7% from the July 30th total of 5,960,000 shares. Based on an average daily trading volume, of 595,500 shares, the short-interest ratio is presently 7.6 days.
View Veracyte's Short Interest

Who are some of Veracyte's key competitors?

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), AbbVie (ABBV), CA (CA), InVitae (NVTA), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Editas Medicine (EDIT), Exelixis (EXEL) and Endologix (ELGX).

Who are Veracyte's key executives?

Veracyte's management team includes the following people:
  • Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
  • Mr. Christopher M. Hall, Pres & COO (Age 50)
  • Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
  • Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)
  • Mr. Ashish Kheterpal, Chief Information Officer

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by many different retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (8.50%), Gilder Gagnon Howe & Co. LLC (6.26%), Sumitomo Mitsui Trust Holdings Inc. (6.28%), Vanguard Group Inc. (5.55%), GW&K Investment Management LLC (2.35%) and New York State Common Retirement Fund (1.67%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy and Robert S Epstein.
View institutional ownership trends for Veracyte

Which institutional investors are selling Veracyte stock?

VCYT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Gilder Gagnon Howe & Co. LLC, William Blair Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., AQR Capital Management LLC, Nuveen Asset Management LLC, UBS Group AG, and Skandinaviska Enskilda Banken AB publ. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, and Robert S Epstein.
View insider buying and selling activity for Veracyte

Which institutional investors are buying Veracyte stock?

VCYT stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Vanguard Group Inc., New York State Common Retirement Fund, Candriam Luxembourg S.C.A., Bank of New York Mellon Corp, Rafferty Asset Management LLC, Swiss National Bank, and Barclays PLC.
View insider buying and selling activity for Veracyte

How do I buy shares of Veracyte?

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $32.72.

How big of a company is Veracyte?

Veracyte has a market capitalization of $1.66 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

What is Veracyte's official website?

The official website for Veracyte is www.veracyte.com.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.